$\"Abstract$ <\/div>\n

$\"Figure\"$ <\/div>\n

Figure VEGFR\/multitargeted inhibitors approved for clinical use.\\<\/p>\n

$\"Figure\"$ <\/p>\n

Quinazoline and quinoline derivatives IN TRIALS<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Abbreviations Used<\/td>\n<\/tr>\n
VEGF<\/td>\n vascular endothelial growth factor<\/td>\n<\/tr>\n
mTOR<\/td>\n mammalian target of rapamycin<\/td>\n<\/tr>\n
TIMP-1<\/td>\n tissue inhibitor of metalloproteinase 1<\/td>\n<\/tr>\n
PlGF<\/td>\n placenta growth factor<\/td>\n<\/tr>\n
VEGFR<\/td>\n vascular endothelial growth factor receptor<\/td>\n<\/tr>\n
TK<\/td>\n tyrosine kinase<\/td>\n<\/tr>\n
Flt<\/td>\n fms-like tyrosine kinase<\/td>\n<\/tr>\n
KDR<\/td>\n kinase insert domain<\/td>\n<\/tr>\n
Flk<\/td>\n fetal liver kinase<\/td>\n<\/tr>\n
JM<\/td>\n juxtamembrane<\/td>\n<\/tr>\n
MAPK<\/td>\n mitogen activated protein kinase<\/td>\n<\/tr>\n
Raf<\/td>\n rapidly accelerated fibrosarcoma<\/td>\n<\/tr>\n
MEK<\/td>\n mitogen activated protein kinase\/extracellular signal-regulated kinase kinase<\/td>\n<\/tr>\n
ERK<\/td>\n extracellular signal-regulated kinase<\/td>\n<\/tr>\n
FAK<\/td>\n focal adhesion kinase<\/td>\n<\/tr>\n
PDGFR<\/td>\n platelet-derived growth factor receptor<\/td>\n<\/tr>\n
CSFR<\/td>\n colony stimulating factor receptor<\/td>\n<\/tr>\n
FLT3<\/td>\n fms-like tyrosine kinase receptor 3<\/td>\n<\/tr>\n
FGF<\/td>\n fibroblast growth factor<\/td>\n<\/tr>\n
HGF<\/td>\n hepatocyte growth factor<\/td>\n<\/tr>\n
IL-8<\/td>\n interleukin 8<\/td>\n<\/tr>\n
Tie-2<\/td>\n tyrosine kinase with immunoglobulin and epidermal growth factor homology domains 2<\/td>\n<\/tr>\n
Eph<\/td>\n erythropoietin-producing human hepatocellular carcinoma receptor<\/td>\n<\/tr>\n
PET<\/td>\n positron emission tomography<\/td>\n<\/tr>\n
NSCLC<\/td>\n non-small-cell lung cancer<\/td>\n<\/tr>\n
Bcr-Abl<\/td>\n breakpoint cluster region Abelson tyrosine kinase<\/td>\n<\/tr>\n
RCC<\/td>\n renal cell carcinoma<\/td>\n<\/tr>\n
HCC<\/td>\n hepatocellular carcinoma<\/td>\n<\/tr>\n
GIST<\/td>\n gastrointestinal stromal tumor<\/td>\n<\/tr>\n
EGFR<\/td>\n epidermal growth factor receptor<\/td>\n<\/tr>\n
RET<\/td>\n rearranged during transfection<\/td>\n<\/tr>\n
CD<\/td>\n catalytic domain<\/td>\n<\/tr>\n
AML<\/td>\n acute myeloid leukemia<\/td>\n<\/tr>\n
FGFR<\/td>\n fibroblast growth factor receptor<\/td>\n<\/tr>\n
HUVEC<\/td>\n human umbilical vein endothelial cell<\/td>\n<\/tr>\n
HER<\/td>\n human epidermal growth factor receptor<\/td>\n<\/tr>\n
Lck<\/td>\n lymphoid cell kinase<\/td>\n<\/tr>\n
ADME<\/td>\n adsorption, distribution, metabolism, and excretion<\/td>\n<\/tr>\n
CML<\/td>\n chronic myeloid leukemia<\/td>\n<\/tr>\n
PLK1<\/td>\n polo-like kinase 1<\/td>\n<\/tr>\n
CDK<\/td>\n cyclin dependent kinase<\/td>\n<\/tr>\n
eNOS<\/td>\n endothelial nitric oxide synthase $\"Physical$ <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"
1-{2-Chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methylisoxazol-3-yl)urea AV-951 \u00a0Tivozanib\u00a0(AV-951) is an oral\u00a0VEGF receptor\u00a0tyrosine kinase\u00a0inhibitor. It is undergoing clinical trial investigation for the treatment of\u00a0renal cell carcinomas.[1] An oral\u00a0quinoline\u00a0urea\u00a0derivative, tivozanib suppresses\u00a0angiogenesis\u00a0by being selectively inhibitory against\u00a0vascular endothelial growth factor.[2]\u00a0It was developed by\u00a0AVEO Pharmaceuticals.[3] It is designed to inhibit all three VEGF receptors.[4] Phase III results on advanced renal cell carcinoma suggest a 30%… Continue reading FDA accepts AVEO-Astellas tivozanib NDA filing for renal cell carcinoma, 29 nov 2012<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[146],"_links":{"self":[{"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/posts\/299"}],"collection":[{"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/comments?post=299"}],"version-history":[{"count":12,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/posts\/299\/revisions"}],"predecessor-version":[{"id":311,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/posts\/299\/revisions\/311"}],"wp:attachment":[{"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/media?parent=299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/categories?post=299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/tags?post=299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}